Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Rated “Moderate Buy” by Sell-Side Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been given a consensus recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $364.95.

Several research analysts have recently weighed in on ALNY shares. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 31st. Oppenheimer cut their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Raymond James Financial upgraded shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price objective on the stock in a report on Monday, August 3rd. Stifel Nicolaus lowered their target price on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st.

Alnylam Pharmaceuticals Trading Down 0.9%

Shares of NASDAQ ALNY traded down $2.20 during midday trading on Friday, hitting $231.83. The stock had a trading volume of 1,404,802 shares, compared to its average volume of 1,301,571. Alnylam Pharmaceuticals has a 1-year low of $197.81 and a 1-year high of $495.55. The company has a fifty day moving average price of $239.35 and a 200 day moving average price of $274.34. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $31.02 billion, a price-to-earnings ratio of 43.09 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter last year, the firm posted ($0.51) EPS. The business’s revenue for the quarter was up 66.9% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals will post 6.68 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares in the company, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ALNY. Wellington Management Group LLP raised its stake in Alnylam Pharmaceuticals by 9.0% during the second quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after buying an additional 174,482 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Alnylam Pharmaceuticals by 7.4% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company’s stock worth $219,104,000 after acquiring an additional 50,329 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $148,128,000. Finally, Swiss National Bank increased its holdings in shares of Alnylam Pharmaceuticals by 7.9% in the 1st quarter. Swiss National Bank now owns 387,720 shares of the biopharmaceutical company’s stock valued at $128,285,000 after acquiring an additional 28,520 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.